Maddalena Sbaffone, Marie-Lise Jaffrain-Rea, Lucia Cappabianca, Francesca Carbonara, Francesca Gianno, Tiziana Feola, Marianna Ruggieri, Veronica Zelli, Rita Maccarone, Stefano Guadagni, Marco Clementi, Antonietta Arcella, Vincenzo Esposito, Giulia Carozza, Ilaria Martelli, Antonietta Rosella Farina, Andrew Reay Mackay
Pituitary neuroendocrine tumors (PitNETs) are generally benign but comprise an aggressive, invasive, therapy-resistant, metastatic subset, underpinning a need for novel therapeutic targets. PitNETs exhibit low mutation rates but are associated with conditions linked to alternative splicing, an alternative oncogene pathway activation mechanism. PitNETs express the neurotrophin receptor TrkA, which exhibits oncogenic alternative TrkAIII splicing in other neuroendocrine tumors. We, therefore, assessed whether TrkAIII splicing represents a potential oncogenic participant in PitNETs...
March 7, 2024: Biology